The benefit of using dolutegravir for HIV treatment in pregnant women outweighs the risk. This is the message delivered by two studies presented at the 23rd International AIDS Conference, which have shown that the drug induces rapid viral suppression and brings a slight but nonsignificant risk of neural tube defects (NTDs) compared with other antiretrovirals.
Access to HIV prevention and treatment services has decreased considerably due to more stringent measures implemented by governments across the globe in response to the novel coronavirus disease (COVID-19) pandemic, according to the results of a study presented at the 23rd International AIDS Conference (AIDS 2020).
At a lower dose, the single-pill drug that combines elvitegravir (EVG), cobicistat, emtricitabine, and tenofovir alafenamide (TAF) has an acceptable safety profile and maintains virological suppression in HIV-infected children, according to the results of a single-arm, open label trial.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.